Dimensional Fund Advisors’s LENZ Therapeutics LENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$381K Sell
41,874
-71,220
-63% -$1M ﹤0.01% 2981
2025
Q4
$1.81M Buy
113,094
+72,208
+177% +$2.1M ﹤0.01% 2753
2025
Q3
$1.9M Hold
40,886
﹤0.01% 2774
2025
Q2
$1.2M Sell
40,886
-895
-2% -$24.3K ﹤0.01% 2860
2025
Q1
$1.07M Buy
41,781
+7,762
+23% +$191K ﹤0.01% 2868
2024
Q4
$983K Sell
34,019
-154
-0.5% -$4.69K ﹤0.01% 2918
2024
Q3
$812K Sell
34,173
-3,017
-8% -$67K ﹤0.01% 2943
2024
Q2
$644K Buy
37,190
+13,653
+58% +$238K ﹤0.01% 2986
2024
Q1
$526K Buy
23,537
+7,038
+43% +$146K ﹤0.01% 3034
2023
Q4
$303K Buy
16,499
+1,918
+13% +$31.7K ﹤0.01% 3134
2023
Q3
$253K Sell
14,581
-444
-3% -$7.72K ﹤0.01% 3177
2023
Q2
$273K Buy
15,025
+7,631
+103% +$152K ﹤0.01% 3182
2023
Q1
$127K Buy
7,394
+348
+5% +$5.63K ﹤0.01% 3275
2022
Q4
$164 Buy
7,046
+5,524
+363% +$128K ﹤0.01% 3258
2022
Q3
$34K Buy
+1,522
New +$36.3K ﹤0.01% 3439

Other funds holding LENZ

Dimensional Fund Advisors's LENZ Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its LENZ Therapeutics (LENZ) stake by 63% in Q1 2026, selling an estimated $1M and leaving 41,874 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #2981.

Dimensional Fund Advisors first reported a position in LENZ in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.9M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Dimensional Fund Advisors held 41,874 shares of LENZ Therapeutics worth $381K as of Q1 2026.
  • Dimensional Fund Advisors sold 71,220 LENZ Therapeutics shares in Q1 2026, an estimated $1M.
  • LENZ Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2981 holding.
  • Dimensional Fund Advisors first reported a position in LENZ Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Dimensional Fund Advisors's LENZ Therapeutics position peaked at $1.9M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.